Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.80 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.80 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.80 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094640 | 1.00 | ABCB1 (0.80) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1094642 | 1.00 | ABCB1 (0.80) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL6051107 | 0.94 | ABCB1 (0.79) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL6051109 | 0.94 | ABCB1 (0.79) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL8143107 | 0.94 | ABCB1 (0.71) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL4344434 | 0.94 | ABCB1 (0.77) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL4344430 | 0.94 | ABCB1 (0.77) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL22580344 | 0.93 | ABCB1 (0.69) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL13617628 | 0.93 | ABCB1 (0.74) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL6061067 | 0.93 | ABCB1 (0.73) | ABCB1KCNE1KCNQ1KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222192-B1 | HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2008-06-18 | — | — | EP | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2005-11-24 | — | — | US | disclosed |
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2005-11-24 | — | — | US | disclosed |
| CN-1191256-C | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) aminol]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARM LTD (IE) | 2005-03-02 | — | — | CN | disclosed |
| US-6649651-B1 | AIDS; human T-cell lymphoma/leukemia virus or lymphadenopathy associated virus treatment | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-18 | — | — | US | disclosed |
| US-6649651-B1 | AIDS; human T-cell lymphoma/leukemia virus or lymphadenopathy associated virus treatment | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-18 | — | — | US | disclosed |
| CN-1407987-A | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) aminol]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC NV (IE) | 2003-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | HPN, DNPEP, DPEP1 | ABCB1 2045/4885KCNE1 4155/4885KCNQ1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.